Skip to main content
Premium Trial:

Request an Annual Quote

Chris Hodkinson, Marc van der Schee, and Hamilton Scanlon

Owlstone Medical has appointed Chris Hodkinson as vice president of business development, Marc van der Schee as lead clinical research scientist, and Hamilton Scanlon as vice president of manufacturing. Hodkinson joins Owlstone from Abcodia, which he co-founded and where he served as director and chief operating officer. Van der Schee joins the company with 10 years of experience in the field of volatile biomarker research. Scanlon joins Owlstone with over 30 years of experience in product development. He has worked at start-up companies and PLCs, and has been responsible for setting up manufacturing facilities within China, Italy, and the UK.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.